Clinical AI risk extends beyond model accuracy

The review organizes risk across multiple stages and layers of clinical AI deployment:

• Design and training data: Manipulated or poisoned data can alter a system’s behavior before it reaches a clinical setting.
• Deployment and interfaces: Prompt injection can introduce malicious instructions into a workflow. The review uses the possibility of a model overlooking a visible tumor to illustrate how an attack at the interface could affect clinical interpretation. Vulnerable hospital infrastructure can also interrupt care or expose patient information.
• Model behavior: LLMs can produce convincing but false medical information, sometimes called hallucinations. They may also agree too readily with a user’s assumptions, reinforcing an incorrect premise rather than challenging it.
• Human–AI interaction: Persuasive answers can encourage automation bias, in which clinicians defer too readily to a system, and confirmation bias, in which they use it to support a conclusion they already favor.
• Institutional use: Clinicians may turn to public or unapproved systems without formal authorization—a form of “shadow use” that can bypass privacy safeguards, local evaluation, accountability and incident reporting.

This lifecycle view matters because a system can perform well in a controlled test and still be unsafe in practice. Security, human behavior, clinical context and organizational controls can all change the outcome.

What responsible deployment would require

The review calls for safety measures that remain active after a system goes live. Those measures include secure development, careful training-data governance, local testing in the intended clinical context, clearly defined human responsibilities and continuous monitoring of performance and incidents.

The practical implication is that hospitals and health systems need to know more than whether a tool produces plausible text. They also need to establish:

• who is permitted to use it and for which tasks;
• what data the system can access and where that data goes;
• how clinicians must verify its outputs;
• who is accountable when an AI-assisted record or recommendation is wrong; and
• how the organization can investigate, pause or withdraw the tool when risks emerge.

The proposed two-level oversight model

To support that accountability, the authors propose two complementary layers of oversight.

Institutional AI-governance teams

Health-care organizations would use dedicated governance teams to approve AI tools, evaluate them locally, define responsibilities and oversee their operation. This keeps decisions connected to the organization’s patients, workflows, infrastructure and professional obligations.

Centralized AI Security Operations Centers

The review also recommends centralized AI Security Operations Centers, or SOCs, that can identify incidents across organizations, share threat signals and coordinate responses. The model reflects the fact that an attack or failure affecting one clinical AI system may reveal a wider vulnerability affecting other institutions as well.

Together, the two layers combine local clinical accountability with broader security intelligence.

Why static medical-device regulation may not be enough

Traditional medical-device frameworks were largely developed around products that could be assessed as relatively stable. Clinical AI software can be different: its behavior and risk profile may shift as models are updated, data distributions change, workflows evolve or attackers develop new techniques.

The result is a regulatory gap. Approval or assessment at one point in time does not automatically demonstrate that a continuously changing system remains safe in every later context. The TU Dresden researchers’ broader work on medical-AI regulation likewise argues that regulatory science needs to keep pace with rapidly developing technologies.

For organizations, this means deployment should be treated as the start of oversight rather than the end of it. Ongoing checks should cover performance, safety, cybersecurity, privacy and equity, with processes for reporting incidents and suspending systems when necessary.

Why patient consent is part of technical safety

The review’s concerns are also visible in the use of AI scribes and other clinical documentation tools. Australian clinical guidance says patients should be informed about an AI system’s purpose, scope, benefits, risks and safety or performance monitoring arrangements. It also makes clear that clinicians remain responsible for the care and records produced with AI assistance.

Professional guidance for Australian general practice further emphasizes that clinicians should understand and test an AI scribe, obtain consent before each use, protect stored data and ensure that the clinical record is accurate.

Recent reporting has described substantial variation in how Australian practices obtain consent, including cases in which a waiting-room sign was treated as sufficient. Australia’s medical regulator has also stressed that clinicians must check AI-generated outputs for accuracy. These reports illustrate why consent cannot be treated as a box-ticking exercise: patients need meaningful information, clinicians need enough technical understanding to use the system safely, and responsibility must remain with the clinician.

The available evidence does not establish how widespread inadequate consent or insufficient understanding is across Australia. It does, however, reinforce the review’s broader argument that transparency, human oversight and organizational accountability are operational safety controls—not administrative details added after deployment.

The practical takeaway for health-care organizations

The review’s message is best understood as a deployment standard rather than a rejection of clinical AI. Large language models may support valuable workflows, but safe adoption requires organizations to treat them as changing sociotechnical systems rather than ordinary software tools.

Before and after deployment, health-care leaders should be prepared to evaluate the model, secure the surrounding infrastructure, train users, explain AI involvement to patients, monitor real-world performance and define who can intervene when the system fails. Until those controls are in place, clinical adoption can continue to outpace the oversight needed to make it trustworthy.

Clinical AI risk extends beyond model accuracy

The review organizes risk across multiple stages and layers of clinical AI deployment:

• Design and training data: Manipulated or poisoned data can alter a system’s behavior before it reaches a clinical setting.
• Deployment and interfaces: Prompt injection can introduce malicious instructions into a workflow. The review uses the possibility of a model overlooking a visible tumor to illustrate how an attack at the interface could affect clinical interpretation. Vulnerable hospital infrastructure can also interrupt care or expose patient information.
• Model behavior: LLMs can produce convincing but false medical information, sometimes called hallucinations. They may also agree too readily with a user’s assumptions, reinforcing an incorrect premise rather than challenging it.
• Human–AI interaction: Persuasive answers can encourage automation bias, in which clinicians defer too readily to a system, and confirmation bias, in which they use it to support a conclusion they already favor.
• Institutional use: Clinicians may turn to public or unapproved systems without formal authorization—a form of “shadow use” that can bypass privacy safeguards, local evaluation, accountability and incident reporting.

This lifecycle view matters because a system can perform well in a controlled test and still be unsafe in practice. Security, human behavior, clinical context and organizational controls can all change the outcome.

What responsible deployment would require

The review calls for safety measures that remain active after a system goes live. Those measures include secure development, careful training-data governance, local testing in the intended clinical context, clearly defined human responsibilities and continuous monitoring of performance and incidents.

The practical implication is that hospitals and health systems need to know more than whether a tool produces plausible text. They also need to establish:

• who is permitted to use it and for which tasks;
• what data the system can access and where that data goes;
• how clinicians must verify its outputs;
• who is accountable when an AI-assisted record or recommendation is wrong; and
• how the organization can investigate, pause or withdraw the tool when risks emerge.

The proposed two-level oversight model

To support that accountability, the authors propose two complementary layers of oversight.

Institutional AI-governance teams

Health-care organizations would use dedicated governance teams to approve AI tools, evaluate them locally, define responsibilities and oversee their operation. This keeps decisions connected to the organization’s patients, workflows, infrastructure and professional obligations.

Centralized AI Security Operations Centers

The review also recommends centralized AI Security Operations Centers, or SOCs, that can identify incidents across organizations, share threat signals and coordinate responses. The model reflects the fact that an attack or failure affecting one clinical AI system may reveal a wider vulnerability affecting other institutions as well.

Together, the two layers combine local clinical accountability with broader security intelligence.

Why static medical-device regulation may not be enough

Traditional medical-device frameworks were largely developed around products that could be assessed as relatively stable. Clinical AI software can be different: its behavior and risk profile may shift as models are updated, data distributions change, workflows evolve or attackers develop new techniques.

The result is a regulatory gap. Approval or assessment at one point in time does not automatically demonstrate that a continuously changing system remains safe in every later context. The TU Dresden researchers’ broader work on medical-AI regulation likewise argues that regulatory science needs to keep pace with rapidly developing technologies.

For organizations, this means deployment should be treated as the start of oversight rather than the end of it. Ongoing checks should cover performance, safety, cybersecurity, privacy and equity, with processes for reporting incidents and suspending systems when necessary.

Why patient consent is part of technical safety

The review’s concerns are also visible in the use of AI scribes and other clinical documentation tools. Australian clinical guidance says patients should be informed about an AI system’s purpose, scope, benefits, risks and safety or performance monitoring arrangements. It also makes clear that clinicians remain responsible for the care and records produced with AI assistance.

Professional guidance for Australian general practice further emphasizes that clinicians should understand and test an AI scribe, obtain consent before each use, protect stored data and ensure that the clinical record is accurate.

Recent reporting has described substantial variation in how Australian practices obtain consent, including cases in which a waiting-room sign was treated as sufficient. Australia’s medical regulator has also stressed that clinicians must check AI-generated outputs for accuracy. These reports illustrate why consent cannot be treated as a box-ticking exercise: patients need meaningful information, clinicians need enough technical understanding to use the system safely, and responsibility must remain with the clinician.

The available evidence does not establish how widespread inadequate consent or insufficient understanding is across Australia. It does, however, reinforce the review’s broader argument that transparency, human oversight and organizational accountability are operational safety controls—not administrative details added after deployment.

The practical takeaway for health-care organizations

The review’s message is best understood as a deployment standard rather than a rejection of clinical AI. Large language models may support valuable workflows, but safe adoption requires organizations to treat them as changing sociotechnical systems rather than ordinary software tools.

Before and after deployment, health-care leaders should be prepared to evaluate the model, secure the surrounding infrastructure, train users, explain AI involvement to patients, monitor real-world performance and define who can intervene when the system fails. Until those controls are in place, clinical adoption can continue to outpace the oversight needed to make it trustworthy.